Table of Contents
ISRN Neurology
Volume 2014, Article ID 956353, 10 pages
http://dx.doi.org/10.1155/2014/956353
Clinical Study

Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings

1QPS Netherlands B.V., Petrus Campersingel 123, 9713 AG Groningen, P.O. Box 137, 9700 AC Groningen, The Netherlands
2Synthon B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands

Received 11 November 2013; Accepted 10 December 2013; Published 22 January 2014

Academic Editors: G. Boysen, G. Meco, and T. Müller

Copyright © 2014 Khalid Abou Farha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Missale, S. Russel Nash, S. W. Robinson, M. Jaber, and M. G. Caron, “Dopamine receptors: from structure to function,” Physiological Reviews, vol. 78, no. 1, pp. 189–225, 1998. View at Google Scholar · View at Scopus
  2. T. Hussain and M. F. Lokhandwala, “Renal dopamine receptors and hypertension,” Experimental Biology and Medicine, vol. 228, no. 2, pp. 134–142, 2003. View at Google Scholar · View at Scopus
  3. J.-M. Beaulieu and R. R. Gainetdinov, “The physiology, signaling, and pharmacology of dopamine receptors,” Pharmacological Reviews, vol. 63, no. 1, pp. 182–217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Farooqui and A. A. Farooqui, “Lipid-mediated oxidativestress and inflammation in the pathogenesis of Parkinson’s disease,” Parkinson's Disease, vol. 2011, Article ID 247467, 9 pages, 2011. View at Publisher · View at Google Scholar
  5. S. Aoyama, H. Kase, and E. Borrelli, “Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an Adenosine A2A receptor antagonist,” The Journal of Neuroscience, vol. 20, no. 15, pp. 5848–5852, 2000. View at Google Scholar · View at Scopus
  6. S. Hisahara and S. Shimohama, “Dopamine receptors and Parkinson’s disease,” International Journal of Medicinal Chemistry, vol. 2011, Article ID 403039, 16 pages, 2011. View at Publisher · View at Google Scholar
  7. D. J. Brooks, “Dopamine agonists: their role in the treatment of Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 68, no. 6, pp. 685–690, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. B. R. Thanvi and T. C. N. Lo, “Long term motor complications of levodopa: clinical features, mechanisms, and management strategies,” Postgraduate Medical Journal, vol. 80, no. 946, pp. 452–458, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. M. Mokhles, G. Trifiro, J. Dieleman et al., “Dopamineagonist and heart failure in patients with Parkinson’s disease: a nested case control study on multiple health care databases,” in Proceedings of the European Society of Cardiology Congress, Stockholm, Sweden, September 2010.
  10. P. A. F. Jansen, R. M. C. Herings, M. M. Samson et al., “Quick titration of pergolide in cotreatment with domperidone is safe and effective,” Clinical Neuropharmacology, vol. 24, no. 3, pp. 177–180, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Kujawa, S. Leurgans, R. Raman, L. Blasucci, and C. G. Goetz, “Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease,” Archives of Neurology, vol. 57, no. 10, pp. 1461–1463, 2000. View at Google Scholar · View at Scopus
  12. F. Contrera, M. Rivera, M. Garcí, N. Ospino, M. A. De la Parte, and M. Velasco, “Dopamine and hypertension,” AVFT, vol. 19, no. 2, 2000. View at Google Scholar
  13. C. Zeng, M. Zhang, L. D. Asico, G. M. Eisner, and P. A. Jose, “The dopaminergic system in hypertension,” Clinical Science, vol. 112, no. 11-12, pp. 583–597, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Senard, S. Raï, M. Lapeyre-Mestre et al., “Prevalence of orthostatic hypotension in Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 63, no. 5, pp. 584–589, 1997. View at Google Scholar · View at Scopus
  15. R. Kirsten, M. Breidert, K. Sparwasser, J. G. Ochs, K. Hesse, and K. Nelson, “Carmoxirole inhibits platelet aggregation in vitro and ex vivo,” International Journal of Clinical Pharmacology and Therapeutics, vol. 33, no. 2, pp. 76–80, 1995. View at Google Scholar · View at Scopus
  16. G. R. Peters, S. F. Francom, and C. E. Wright, “Cardiovascular and hormonal effects of Pramipexole, a novel dopamine agonist. American society for clinical pharmacology and therapeutics,” Clincal Pharmacology & Therapeutics, vol. 59, p. 178, 1996. View at Publisher · View at Google Scholar
  17. M. M. Hoehn, Parkinson's Disease, chapter 10, Chapman and Hall Medical, 1990, Quoted from Prothero JD: The Treatment of Parkinson's disease, 1995, http://www.hitl.washington.edu/publications/prothero/node11.html.
  18. B. Asha, N. Hansali, and P. Apoorva, “Successful birth of an IVF baby in a patient with Parkinson’s disease,” Journal of Human Reproductive Sciences, vol. 3, no. 1, pp. 42–43, 2010. View at Publisher · View at Google Scholar
  19. K. Abou Farha, R. Abou Farha, and M. Bolt, “The acute impact of smoking one cigarette on cardiac hemodynamic parameters,” Cardiology Research, vol. 2, no. 2, pp. 58–65, 2011. View at Google Scholar
  20. S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, “Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies,” The Lancet, vol. 360, no. 9349, pp. 1903–1913, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. Å. Hjalmarson, “Heart rate: an independent risk factor in cardiovascular disease,” European Heart Journal, vol. 9, Supplement F, pp. F3–F7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Benetos, A. Rudnichi, F. Thomas, M. Safar, and L. Guize, “Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure,” Hypertension, vol. 33, no. 1, pp. 44–52, 1999. View at Google Scholar · View at Scopus
  23. M. T. Cooney, E. Vartiainen, T. Laakitainen, A. Juolevi, A. Dudina, and I. M. Graham, “Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women,” American Heart Journal, vol. 159, no. 4, pp. 612–619, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Aboyans, M. Frank, K. Nubret, P. Lacroix, and M. Laskar, “Heart rate and pulse pressure at rest are major prognostic markers of early postoperative complications after coronary bypass surgery,” European Journal of Cardio-Thoracic Surgery, vol. 33, no. 6, pp. 971–976, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. M. Okin, S. E. Kjeldsen, S. Julius et al., “All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy,” European Heart Journal, vol. 31, no. 18, pp. 2271–2279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Dart and B. A. K. Kingwell, “Pulse pressure—a review of mechanisms and clinical relevance,” Journal of the American College of Cardiology, vol. 37, pp. 975–984, 2001. View at Publisher · View at Google Scholar
  27. C. U. Chae, M. A. Pfeffer, R. J. Glynn, G. F. Mitchell, J. O. Taylor, and C. H. Hennekens, “Increased pulse pressure and risk of heart failure in the elderly,” Journal of the American Medical Association, vol. 281, no. 7, pp. 634–639, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Casiglia, V. Tikhonoff, A. Mazza, A. Piccoli, and A. C. Pessina, “Pulse pressure and coronary mortality in elderly men and women from general population,” Journal of Human Hypertension, vol. 16, no. 9, pp. 611–620, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Benetos, M. Safar, A. Rudnichi et al., “Pulse pressure: a predictor of long-term cardiovascular mortality in a french male population,” Hypertension, vol. 30, no. 6, pp. 1410–1415, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. J. J. van Der Heijden-Spek, J. A. Staessen, R. H. Fagard, A. P. Hoeks, H. A. Struijker Boudier, and L. M. van Bortel, “Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: a population study,” Hypertension, vol. 35, no. 2, pp. 637–642, 2000. View at Google Scholar · View at Scopus
  31. A. P. Avolio, S. G. Chen, and R. P. Wang, “Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community,” Circulation, vol. 68, no. 1, pp. 50–58, 1983. View at Google Scholar · View at Scopus
  32. R. Segan, V. Gupta, L. Walia, and N. Mittal, “Rate pressure product predicts cardiovascular risk in type 2 diabetics with cardiac autonomic neuropathy,” National Journal of Physiology, Pharmacy and Pharmacology, vol. 3, no. 1, pp. 43–47, 2013. View at Publisher · View at Google Scholar
  33. E. G. Lakatta, “Cardiovascular reserve capacity in healthy older humans,” Aging, vol. 6, no. 4, pp. 213–223, 1994. View at Google Scholar · View at Scopus
  34. H. Oxenham and N. Sharpe, “Cardiovascular aging and heart failure,” European Journal of Heart Failure, vol. 5, no. 4, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. S. W. Watts, N. L. Kanagy, and J. H. Lombard, “Receptor-mediated events in the microcirculation,” in Handbook of Physiology, Microcirculation, R. F. Tuma, W. Duran, and K. Lee, Eds., Part II regulation of the microvascular blood flow, Chapter 7, pp. 285–349, Elesvier, Amsterdam, The Netherlands, 2nd edition, 2008. View at Google Scholar
  36. S. Jain and D. S. Goldstein, “Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis,” Neurobiology of Disease, vol. 46, pp. 572–580, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Imrich, B. A. Eldadah, O. Bentho et al., “Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension,” Parkinsonism and Related Disorders, vol. 15, no. 2, pp. 122–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. M. Senard, P. Valet, G. Durrieu et al., “Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension,” European Journal of Clinical Investigation, vol. 20, no. 6, pp. 613–619, 1990. View at Google Scholar · View at Scopus
  39. H. A. Sahyoun, B. Costall, and R. J. Naylor, “On the ability of domperidone to selectively inhibit catecholamine-induced relaxation of circular smooth muscle of guinea pig stomach,” Journal of Pharmacy and Pharmacology, vol. 34, no. 1, pp. 27–33, 1982. View at Publisher · View at Google Scholar · View at Scopus
  40. J. S. Gidda and I. Monkovic, “Gastrointestinal motility enhancing agents,” in Annual Reports in Medicinal Chemistry, D. M. Baily, Ed., vol. 20, Section II (pharmacodynamic agents), Chapter 12, p. 117, Academic Press, Oralndo, Fla, USA, 1985. View at Google Scholar
  41. I. Martinez-Mir, E. Rubio, L. Estan, and F. J. Morales-Olivas, “Effect of domperidone on the contractility of isolated guinea-pig atria,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 10, no. 10, pp. 613–617, 1988. View at Google Scholar · View at Scopus